Fenfluramine effectively reduces seizure in patients with Dravet Syndrome: Study
USA: Fenfluramine is well-tolerated and helps to control seizures for a long period in patients with Dravet syndrome, suggests a recent study in the journal Epilepsia.
Recent randomized, placebo‐controlled clinical trials have shown fenfluramine to provide significant reductions in convulsive seizure frequency in children and adolescents (aged 2‐18 years) with Dravet syndrome. The objective of this study by Joseph Sullivan, University of California San Francisco, San Francisco, CA, USA, and colleagues was to assess longer‐term safety and efficacy of fenfluramine in patients who completed one of the double‐blind studies and entered an open‐label extension (OLE) study.
232 patients enrolled in the OLE study were initiated fenfluramine at 0.2 mg/kg/d regardless of their treatment assignment in the double‐blind study. After 4 weeks, the fenfluramine dose could be titrated based on efficacy and tolerability to maximum of 0.7 mg/kg/d (absolute maximum 27 mg/d) or maximum of 0.4 mg/kg/d (absolute maximum 17 mg/d) in patients receiving concomitant stiripentol. The number and type of seizures were recorded daily in an electronic diary, and safety, including echocardiography, was assessed at Months 1, 2, and 3, and at 3‐month intervals thereafter.
Key findings of the study include:
- Over the entire OLE analysis period, the median decrease in convulsive seizure frequency compared to baseline in the double‐blind studies was −66.8% (range = −100% to 234.9%).
- The median reduction in seizure frequency was similar in patients <6 (−75.7%) and ≥6 years old (−64.7%).
- The most commonly reported adverse events included pyrexia (21.6%), nasopharyngitis (19.4%), and decreased appetite (−15.9%).
- No valvular heart disease (VHD) or pulmonary arterial hypertension (PAH) was observed.
"Study results demonstrate that fenfluramine provides clinically meaningful (≥50%) seizure frequency reduction over an extended period in patients with Dravet syndrome. No patient developed VHD or PAH, and fenfluramine was generally well tolerated," concluded the authors.
"Fenfluramine HCl (Fintepla®) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study," is published in the journal Epilepsia.
DOI: https://onlinelibrary.wiley.com/doi/10.1111/epi.16722
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.